253 related articles for article (PubMed ID: 31287604)
1. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
2. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
3. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
4. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
5. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
[TBL] [Abstract][Full Text] [Related]
7. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
9. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
10. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
[TBL] [Abstract][Full Text] [Related]
11. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
12. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
Azevedo A; Torres T
Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
[TBL] [Abstract][Full Text] [Related]
13. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
16. Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
Chigutsa E; Velez de Mendizabal N; Chua L; Heathman M; Friedrich S; Jackson K; Reich K
J Clin Pharmacol; 2018 Nov; 58(11):1489-1500. PubMed ID: 29878382
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.
Wilsmann-Theis D; Schnell LM; Ralser-Isselstein V; Bieber T; Schön MP; Hüffmeier U; Mössner R
J Dermatol; 2018 Jul; 45(7):850-854. PubMed ID: 29655177
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
Warren RB; Brnabic A; Saure D; Langley RG; See K; Wu JJ; Schacht A; Mallbris L; Nast A
Br J Dermatol; 2018 May; 178(5):1064-1071. PubMed ID: 29171861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
